阿托伐他汀与氯吡格雷联合应用于脑梗死治疗中的价值

Value of Atorvastatin Combined with Clopidogrel in the Treatment of Cerebral Infarction

目的探讨阿托伐他汀与氯吡格雷联合应用于脑梗死患者治疗中的临床价值。方法选取本院于2015年3月至2019年3月期间收治的86例脑梗死患者作为研究资料,依据随机数字抽取表法分组,对照组43例患者采用常规基础治疗,观察组43例患者在常规基础治疗上增加阿托伐他汀与氯吡格雷联合治疗,评价两组患者的治疗效果,神经功能缺损评分、日常生活能力及C反应蛋白变化。结果治疗后,观察组患者总胆固醇、三酰甘油明显改善,且改善程度显著优于对照组,P <0.05;治疗后,观察组患者神经功能缺损明显降低,日常生活能力评分明显提升,C反应蛋白水平恢复正常,且与对照组比较改善优势明显,P <0.05;观察组患者治疗有效率为95.35%,对照组为79.07%,比较差异显著,P <0.05。结论脑梗死患者在常规基础治疗上配合阿托伐他汀与氯吡格雷治疗可进一步保证治疗效果,尤其对改善神经功能、日常生活能力效果较好,利于降低C反应蛋白水平,属于可靠的治疗方案,值得推广。

Objective To investigate the clinical value of atorvastatin combined with clopidogrel in the treatment of cerebral infarction patients.Methods Our hospital in March 2015 to March 2019 were part of the cerebral infarction patients as research materials,a total of 86 cases according to random number table extraction group,control group,43 cases of the conventional foundation treatment,the observation group 43 cases,adding atorvastatin associated with clopidogrel treatment on the basis of conventional treatment,to evaluate the treatment effect,two groups of neural function defect scale changes,daily life ability and C-reactive protein.Results After treatment,total cholesterol and triglycerides in the observation group were signifi cantly improved,and were signifi cantly better than those in the control group(P<0.05).After treatment,neurological defects were significantly reduced in the observation group,and the score of daily living ability was signifi cantly improved,the C-reactive protein level was restored to normal,and the improvement advantage was obvious compared with the control group(P<0.05).The eff ective rate was 95.35%in the observation group and 79.07%in the control group,with signifi cant diff erence(P<0.05).Conclusion In patients with cerebral infarction,the combination of atorvastatin and clopidogrel on the basis of conventional treatment can further ensure excellent eff ects,especially on improving neurological function and daily living ability,and conducive to reducing the level of C-reactive protein,which is a reliable treatment program and worthy of promotion.